https://www.pharmacompass.com/radio-compass-phisper always 0.8 https://www.pharmacompass.com/radio-compass-phisper/gsk-acquires-nuvalent-for-us-10-6-bn-to-expand-its-oncology-portfolio-roche-inks-up-to-us-2-3-bn-deal-with-nurix yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-approves-wockhardt-s-antibiotic-for-complicated-utis-pfizer-inks-up-to-us-10-5-billion-deal-with-innovent yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/lilly-buys-three-vaccine-drugmakers-in-deals-worth-up-to-us-3-8-bn-fda-approves-abbvie-s-ultra-rare-blood-cancer-drug yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-issues-warning-letter-to-chinese-supplier-of-semaglutide-approves-astrazeneca-s-new-treatment-for-hypertension yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-chief-marty-makary-resigns-after-rocky-tenure-italy-s-angelini-to-buy-catalyst-pharma-for-us-4-1-billion yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-issues-warning-letter-to-intas-plant-in-north-india-okays-axsome-s-drug-for-alzheimer-s-related-agitation yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/india-s-sun-pharma-acquires-organon-for-about-us-11-75-bn-lilly-to-buy-ajax-therapeutics-for-up-to-us-2-3-bn yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/lilly-buys-biotech-kelonia-for-up-to-us-7-bn-trump-orders-priority-review-of-psychedelic-drugs-to-treat-mental-illnesses yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-seeks-more-safety-data-from-lilly-on-obesity-drug-foundayo-novo-partners-openai-to-speed-up-drug-development yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/neurocrine-buys-soleno-for-us-2-9-bn-novo-says-wegovy-pill-outperforms-lilly-s-foundayo-in-cross-trial-comparison yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/lilly-in-us-7-8-bn-deal-to-acquire-centessa-for-its-sleep-disorder-pipeline-bags-fda-nod-for-obesity-med-orforglipron yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/merck-buys-terns-pharma-for-us-6-7-bn-to-boost-cancer-portfolio-novartis-acquires-synnovation-unit-for-up-to-us-3bn yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-approves-j-j-s-plaque-psoriasis-pill-federal-judge-blocks-key-parts-of-rfk-jr-s-childhood-vaccine-policy-overhaul yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/lilly-to-invest-us-3-bn-in-china-to-boost-supply-of-new-obesity-drug-servier-acquires-day-one-biopharma-for-us-2-5-bn yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/moderna-resolves-vaccine-patent-dispute-with-roivant-arbutus-fda-grants-accelerated-approval-to-ascendis-dwarfism-therapy yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/gilead-buys-arcellx-for-us-7-8-billion-fda-approves-vanda-s-antipsychotic-pill-for-bipolar-disorder-schizophrenia yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-agrees-to-review-moderna-s-amended-mrna-based-flu-vaccine-application-lilly-builds-orforglipron-stock-ahead-of-approval yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-refuses-to-review-moderna-s-mrna-based-flu-vaccine-application-lilly-buys-orna-for-up-to-us-2-4-billion yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/lilly-expects-25-growth-novo-sees-its-sales-drop-in-2026-amgen-turns-down-fda-request-to-withdraw-rare-disease-drug yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/us-exits-who-moderna-to-stop-investing-in-new-late-stage-vaccine-trials-due-to-increased-opposition-to-immunizations yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/j-j-s-2026-sales-may-cross-us-100-bn-fda-delays-fast-track-reviews-of-drugs-under-trump-s-voucher-program yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/abbvie-inks-us-5-6-bn-oncology-deal-with-china-s-remegen-astra-buys-modella-ai-to-speed-up-cancer-drug-research yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/sanofi-earendil-labs-ink-up-to-us-2-56-bn-ai-driven-autoimmune-drug-deal-cdc-revises-childhood-immunization-guidelines yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/biomarin-inks-us-4-8-billion-rare-disease-deal-with-amicus-fda-approves-pill-version-of-novo-s-wegovy yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-okays-gsk-s-exdensur-as-first-biologic-add-on-med-for-severe-asthma-issues-oai-status-to-sun-pharma-s-india-facility yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/lilly-to-invest-us-6-bn-in-new-api-plant-in-alabama-biocon-buys-remaining-stake-in-biocon-biologics-makes-it-100-subsidiary yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/lilly-cuts-price-of-zepbound-leaked-memo-on-child-deaths-due-to-covid-vaccines-triggers-reaction-from-former-fda-chiefs yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/lilly-becomes-first-pharma-to-hit-us-1-tn-valuation-fda-clears-padcev-keytruda-combo-for-bladder-cancer yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/merck-to-buy-cidara-for-us-9-2-bn-to-strengthen-infectious-disease-portfolio-j-j-to-acquire-halda-for-us-3-05-bn yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pfizer-seals-up-to-us-10-bn-deal-for-metsera-fda-lifts-black-box-warning-on-hormone-therapies-for-menopause yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pfizer-novo-escalate-bidding-war-for-obesity-drug-developer-metsera-kimberly-clark-to-buy-kenvue-for-us-48-7-bn yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/innovent-takeda-ink-up-to-us-11-4-bn-oncology-deal-fda-clears-novo-s-rybelsus-to-reduce-heart-risk-in-diabetics yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novo-targets-mash-with-up-to-us-5-2bn-akero-buy-bms-acquires-cell-therapy-developer-orbital-for-us-1-5-bn yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/chiesi-arbor-in-us-2-bn-gene-therapy-deal-lilly-to-invest-over-us-1-bn-in-india-fda-clears-boehringer-s-rare-lung-disease-dru yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/trump-pfizer-seal-deal-to-offer-drug-discounts-fda-approves-eli-lilly-s-oral-breast-cancer-pill yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pfizer-buys-metsera-for-up-to-us-7-3-bn-roche-acquires-89bio-fda-okays-injectable-version-of-merck-s-keytruda yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-inks-us-5-7-bn-licensing-deal-with-monte-rosa-for-immune-related-diseases-gsk-lilly-pledge-more-investments-in-us yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/advent-to-sell-generic-unit-to-pe-firm-gtcr-for-us-4-8-billion-novo-shapes-up-for-obesity-race-by-cutting-9-000-jobs yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-inks-us-5-2-bn-cardiology-deal-with-china-s-argo-us-2-bn-deal-with-arrowhead-fda-okays-first-glp-1-generic-for-weight yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/white-house-sacks-cdc-director-fda-okays-ionis-dawnzera-first-rna-based-preventive-for-hereditary-angioedema yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-grants-accelerated-approval-to-wegovy-for-treating-mash-lilly-superluminal-ink-us-1-3-bn-ai-deal-to-treat-obesity yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-grants-accelerated-nod-to-boehringer-s-lung-cancer-med-reinstates-ousted-cber-chief-vinay-prasad yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/trump-says-pharma-tariffs-may-touch-250-in-18-months-fda-okays-jazz-pharma-s-rare-brain-tumor-drug yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/consortium-makes-us-3-bn-offer-to-buy-bavarian-nordic-fda-approves-ptc-s-rare-genetic-disorder-drug yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/astra-to-invest-us-50-bn-in-us-to-avoid-tariffs-dr-reddy-s-to-launch-generic-wegovy-in-87-countries-next-year yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/sarepta-lays-off-500-employees-post-second-death-in-elevidys-trial-fda-chief-proposes-lowering-pdufa-fee yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/merck-buys-verona-for-us-10-bn-gains-its-copd-med-summit-astra-reportedly-in-talks-for-us-15-bn-cancer-drug-deal yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/abbvie-doubles-down-on-immunology-with-us-2-1-bn-capstan-buyout-india-s-torrent-buys-controlling-stake-in-jb-chem yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/royalty-pharma-inks-us-2-bn-cancer-drug-deal-with-revolution-astra-daiichi-s-datroway-wins-us-approval-for-lung-cancer yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/lilly-acquires-gene-editing-firm-verve-for-us-1-3-bn-biontech-buys-curevac-astra-signs-us-5-3-bn-ai-deal-with-china-s-cspc yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/rfk-jr-fires-all-17-members-of-cdc-s-vaccine-committee-merck-s-oral-cholesterol-drug-meets-goals-in-late-stage-trials yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/bms-partners-biontech-in-us-11-bn-cancer-drug-deal-sanofi-to-acquire-blueprint-medicines-for-us-9-5-bn yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/lilly-expands-pain-pipeline-via-us-1-bn-siteone-buyout-us-cancels-funding-for-moderna-s-bird-flu-vaccine yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pfizer-inks-us-6-bn-oncology-deal-with-china-s-3sbio-biontech-to-invest-us-1-3-bn-in-uk-for-new-r-d-ai-centers yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/trump-signs-most-favored-nation-executive-order-to-slash-drug-costs-sanofi-takeda-pledge-mega-investments-in-us yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/bms-to-invest-us-40-bn-to-boost-us-manufacturing-r-d-19-states-sue-trump-admin-for-gutting-health-agencies yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/abbvie-amgen-thermo-fisher-to-invest-in-us-manufacturing-to-avoid-tariffs-merck-kgaa-acquires-springworks-for-us-3-9-bn yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/roche-announces-us-50-bn-investment-in-us-to-avoid-tariffs-regeneron-signs-us-3-bn-onshoring-deal-with-fujifilm yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-to-invest-us-23-bn-in-us-to-avoid-import-tariffs-pfizer-halts-development-of-glp-1-weight-loss-pill yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pharma-tariffs-coming-soon-warns-trump-gsk-lilly-ink-billion-dollar-deals-for-blood-brain-barrier-technology yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/cber-director-forced-out-in-fda-gutting-sanofi-alnylam-s-rnai-therapy-qfitlia-wins-us-approval-for-hemophilia-a-b yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/j-j-plans-us-55-bn-investment-in-us-to-avoid-trump-s-tariffs-astra-to-invest-us-2-5-bn-in-chinese-r-d-centre yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/mallinckrodt-endo-merge-in-us-6-7-bn-deal-astra-buys-cell-therapy-developer-esobiotec-pfizer-sells-entire-stake-in-haleon yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/roche-buys-rights-to-zealand-s-obesity-med-in-us-5-3-bn-deal-merck-wins-gardasil-lawsuit-bolsters-vaccine-manufacturing yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/abbvie-enters-obesity-race-with-us-2-23-bn-deal-with-denmark-s-gubra-roche-s-tnkase-approved-for-treating-strokes yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/lilly-to-invest-us-27-bn-in-us-as-trump-threatens-big-pharma-with-tariffs-fda-scrambles-to-rehire-after-mass-layoffs yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/us-health-agencies-brace-for-more-layoffs-under-rfk-jr-novo-alleges-fraud-in-us-1-3-bn-deal-with-kbp-biosciences yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/bain-buys-mitsubishi-tanabe-for-us-3-4-bn-novartis-acquires-anthos-for-us-3-1-bn-fda-okays-abbvie-pfizer-s-new-antibiotic yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-okays-vertex-s-non-opioid-painkiller-supernus-wearable-device-for-parkinson-s-sanofi-gsk-plan-share-buybacks yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-approves-ozempic-to-treat-ckd-in-diabetes-patients-abbvie-neomorph-ink-us-1-64-bn-deal-for-molecular-glue-degraders yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/trump-withdraws-us-from-who-novo-s-ozempic-wegovy-among-15-new-drugs-chosen-for-price-negotiations-under-ira yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/j-j-buys-intra-cellular-for-us-14-6-bn-ftc-exposes-pbms-us-7-3-bn-drug-price-markup-scheme yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novo-bets-up-to-us-4-6-bn-on-ai-drug-development-expands-deal-with-valo-health-wuxi-sells-irish-vaccine-plant-to-merck yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/lilly-s-zepbound-becomes-first-fda-approved-therapy-for-sleep-apnea-novo-wins-nod-for-daily-hemophilia-shot yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novo-invests-us-1-2-bn-in-new-rare-disease-plant-in-denmark-fda-approves-two-drugs-for-atopic-dermatitis yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/lilly-amgen-inject-billions-into-manufacturing-gsk-s-blenrep-bests-world-s-top-selling-myeloma-drug yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-snaps-up-ptc-s-huntington-s-disease-program-in-us-2-9-bn-deal-sanofi-to-set-up-insulin-facility-in-china yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/sarepta-inks-us-11-bn-rna-deal-with-arrowhead-roche-expands-car-t-arsenal-novartis-buys-kate-for-us-1-bn yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/merck-inks-us-3-3-bn-cancer-deal-with-lanova-vaccine-makers-stocks-tumble-after-trump-picks-rfk-jr-to-head-hhs yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/astra-invests-us-2-bn-in-us-r-d-key-abbvie-asset-from-us-8-7-bn-cerevel-buy-flunks-phase-2-trials yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/astra-faces-probe-in-china-abbvie-evolveimmune-ink-potential-us-1-4-bn-deal-ec-levies-us-503-mn-fine-on-teva yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/abbvie-strengthens-alzheimer-s-pipeline-with-us-1-4-bn-aliada-buyout-roche-expands-gene-therapy-pact-with-dyno yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/sanofi-to-sell-50-stake-in-opella-to-cd-r-to-retain-french-workforce-abbvie-bags-fda-nod-for-parkinson-s-therapy-vyalev yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/lundbeck-acquires-longboard-for-us-2-6-billion-roche-s-itovebi-bags-fda-nod-for-breast-cancer yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/bms-med-wins-landmark-fda-nod-for-schizophrenia-sanofi-s-dupixent-approved-to-treat-copd yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/sanofi-gets-two-bids-valuing-its-consumer-unit-at-us-17-bn-pfizer-pulls-scd-drug-from-market yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-panel-votes-against-intercept-s-liver-med-ocaliva-lilly-s-ebglyss-wins-approval-for-eczema yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/gsk-s-copd-long-acting-asthma-drugs-score-late-stage-wins-novo-s-weight-loss-drug-saxenda-found-to-be-safe-in-kids yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-approves-emergent-s-smallpox-vaccine-for-mpox-lilly-inks-up-to-us-1-bn-deal-with-haya-to-target-obesity yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/lilly-pfizer-move-to-sell-drugs-directly-to-consumers-blast-at-indian-drug-factory-kills-17 yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/ira-price-talks-conclude-three-meds-dominate-savings-gilead-s-livdelzi-from-cymabay-buyout-gets-fda-okay yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-rejects-first-mdma-therapy-to-treat-ptsd-merck-curon-ink-up-to-us-1-3-bn-deal-for-next-gen-bispecific-antibody yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-approves-first-ever-t-cell-receptor-gene-therapy-from-adaptimmune-servier-s-brain-tumor-pill yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/boehringer-boosts-immune-oncology-pipeline-with-us-1-3-bn-nerio-buy-pfizer-adds-us-1-bn-to-2024-outlook yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/merck-s-rsv-jab-shows-efficacy-in-infants-novo-lilly-weight-loss-rivalry-intensifies-as-china-okays-tirzepatide yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/us-senate-passes-bipartisan-bill-to-cut-pharma-patent-abuses-ipsen-inks-another-adc-deal yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/lilly-to-acquire-ibd-drug-developer-morphic-for-us-3-2-bn-pfizer-s-r-d-chief-to-step-down yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/lilly-s-alzheimer-s-drug-gets-fda-nod-gsk-buys-rights-to-mrna-vaccines-from-curevac-for-us-1-56-bn yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novo-invests-us-4-1-bn-to-boost-wegovy-ozempic-supply-verona-s-copd-therapy-bags-fda-nod yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/merck-wins-fda-nod-for-pneumococcal-vaccine-roche-partners-ascidian-to-develop-novel-gene-therapies yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-panel-backs-lilly-s-alzheimer-s-drug-agency-approves-ipsen-s-med-to-treat-rare-liver-disease yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/astra-s-cancer-drugs-impress-at-asco-moderna-s-mresvia-becomes-first-mrna-rsv-vaccine-approved-by-fda yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/lilly-to-invest-additional-us-5-3-bn-to-boost-obesity-drug-supply-fda-panel-votes-against-novo-s-weekly-insulin yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/astra-targets-us-80-bn-revenue-by-2030-invests-us-1-5-bn-in-adc-plant-lilly-s-weekly-insulin-scores-late-stage-wins yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/france-draws-us-2-25-bn-investment-from-big-pharma-sanofi-strikes-us-1-2-bn-deal-with-novavax yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-to-consider-psychedelic-assisted-drug-for-treating-ptsd-novartis-buys-mariana-oncology-for-up-to-us-1-75-bn yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/ftc-disputes-relevance-of-over-300-patent-listings-japan-s-ono-to-buy-deciphera-for-us-2-4-bin yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/immunitybio-bags-maiden-fda-nod-for-bladder-cancer-ipsen-skyhawk-partner-to-develop-neurological-therapies yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/us-panel-accuses-china-of-subsidizing-fentanyl-production-nigeria-introduces-5-in-1-meningitis-vaccine yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/vertex-buys-alpine-immune-sciences-for-us-4-9-billion-merck-kgaa-signs-adc-deal-with-ai-biotech-caris yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/genmab-buys-profoundbio-for-us-1-8-bn-fda-okays-vanda-s-fanapt-to-treat-bipolar-disorder yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novo-buys-cardior-pharma-for-up-to-us-1-1-bn-fda-okays-two-meds-for-pulmonary-arterial-hypertension yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/madrigal-s-rezdiffra-becomes-first-fda-approved-drug-to-treat-nash-astra-buys-fusion-for-us-2-4-bn yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-approves-wegovy-to-reduce-cardiovascular-risks-delays-action-on-lilly-s-alzheimer-s-drug yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/court-dismisses-astra-s-lawsuit-over-ira-price-talks-ozempic-shows-benefits-to-kidney-heart-in-diabetics-with-ckd yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/india-to-have-bms-largest-r-d-facility-after-us-its-drug-plants-to-face-increased-fda-inspections yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-okays-iovance-s-cell-therapy-for-skin-cancer-issues-warning-letter-to-china-s-sichuan-deebio yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/gilead-acquires-cymabay-for-us-4-3-bn-exscientia-sacks-founder-ceo-andrew-hopkins yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novo-s-parent-buys-catalent-for-us-16-5-bn-lilly-calls-for-scrutiny-novartis-acquires-morphosys yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/vertex-s-non-opioid-painkiller-succeeds-in-late-stage-trials-fda-finalizes-car-t-guidance yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/six-car-t-therapies-to-carry-boxed-warning-for-secondary-cancer-sanofi-buys-inhibrx-for-about-us-2-2-billion yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/lilly-to-launch-zepbound-in-more-markets-this-year-casgevy-bags-second-fda-nod yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-allows-florida-to-import-drugs-from-canada-india-mandates-new-gmp-standards-for-drugmakers yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/bms-buys-karuna-for-us-14-billion-astra-ionis-nerve-damage-drug-bags-fda-nod yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-finds-major-lapses-at-moderna-s-covid-vax-facility-servier-ordered-to-pay-millions-in-deadly-mediator-scandal yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-okays-two-gene-therapies-for-sickle-cell-disease-us-frames-policy-to-seize-drug-patents yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/abbvie-acquires-immunogen-cerevel-roche-joins-obesity-med-race-with-carmot-buy yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-probes-serious-risks-of-car-t-therapies-sanofi-s-dupixent-posts-trial-gains-in-treating-copd yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/britain-authorizes-gene-therapy-for-blood-disorders-bayer-s-anticoagulant-fails-late-stage-trial yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/obesity-market-hots-up-as-novo-invests-us-6-bn-in-capacity-expansion-fda-okays-first-chikungunya-jab yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/us-uk-okay-lilly-s-mounjaro-for-weight-loss-ftc-questions-over-100-orange-book-patents yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/gsk-buys-rights-to-j-j-s-hepatitis-therapy-lilly-s-omvoh-okayed-for-treating-ulcerative-colitis yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pfizer-s-ulcerative-colitis-drug-bags-fda-nod-novo-to-buy-bp-med-for-us-1-3-billion yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/bms-to-buy-mirati-for-up-to-us-5-8-billion-gsk-inks-us-3-billion-shingrix-deal-with-zhifei yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/viatris-to-divest-us-3-6-billion-worth-of-businesses-sanofi-teva-in-us-1-5-billion-ibd-deal yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/astra-daiichi-s-drug-scores-win-in-late-stage-breast-cancer-study-novartis-to-spin-off-sandoz-on-oct-4 yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-flags-quality-issues-at-novo-s-clayton-plant-j-j-renews-identity-after-135-years yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/hhs-assails-merck-over-ira-lawsuit-moderna-partners-immatics-for-cancer-jabs yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-sues-us-govt-over-medicare-drug-price-regulation-ftc-okays-amgen-horizon-deal yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/us-names-first-10-drugs-to-face-price-negotiations-novo-s-wegovy-reduces-heart-failure-in-obese yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/two-regeneron-drugs-bag-approval-fda-chief-links-drug-shortages-to-low-priced-generics yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-grants-accelerated-nods-to-j-j-pfizer-s-blood-cancer-therapies-ipsen-s-rare-disease-drug-approved yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/nektar-sues-lilly-over-incorrect-analysis-of-rezpeg-data-novo-s-wegovy-reduces-heart-attack-risk-by-20 yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/biogen-to-acquire-reata-for-us-7-3-billion-gsk-sues-pfizer-for-violation-of-its-rsv-jab-patents yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pfizer-s-nc-facility-damaged-by-tornado-may-worsen-drug-shortages-biogen-to-cut-1-000-jobs yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/lilly-s-donanemab-slows-early-alzheimer-s-by-60-fda-okays-sanofi-astra-s-rsv-therapy-for-babies yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/eisai-biogen-s-leqembi-bags-fda-s-full-approval-teva-may-sell-api-unit-for-us-2-bn yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-okays-biomarin-s-us-2-9-mn-gene-therapy-for-hemophilia-a-moderna-forays-into-china-with-mrna-drugs yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-grants-accelerated-nod-to-sarepta-s-us-3-2-mn-dmd-therapy-rejects-higher-dose-variant-of-regeneron-s-eylea yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/lilly-to-buy-dice-therapeutics-for-us-2-4-bn-astra-may-spin-off-china-biz yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/trade-body-sues-us-govt-over-ira-novartis-buys-chinook-for-up-to-us-3-5-billion yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/merck-sues-us-govt-over-ira-fda-allows-import-of-unapproved-chemo-drug-from-china-to-alleviate-shortage yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-approves-pfizer-s-rsv-vaccine-okays-lexicon-s-inpefa-as-treatment-for-heart-failure yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/soaring-demand-for-obesity-drug-wegovy-prompts-novo-to-halt-promos-teva-to-cut-down-generics-production yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/ftc-files-lawsuit-to-block-amgen-horizon-deal-fda-panel-backs-accelerated-nod-for-sarepta-s-therapy-for-dmd yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/astra-s-farxiga-bags-fda-nod-to-treat-heart-failure-post-cough-syrup-deaths-fda-issues-guidance-for-testing-toxic-contaminants yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/gsk-wins-rsv-vaccine-race-with-first-fda-nod-lilly-s-drug-slows-alzheimer-s-by-35-in-late-stage-trial yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-biogen-trim-pipelines-europe-proposes-major-changes-to-its-pharma-laws yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/merck-buys-prometheus-for-us-10-8-bn-fda-grants-full-approval-to-roche-s-polivy-for-lymphoma yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pharma-executives-call-for-reversal-of-ban-on-abortion-pill-merck-eisai-s-drug-combo-fails-cancer-trials yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/j-j-offers-us-8-9-bn-to-resolve-talc-lawsuits-global-pharma-violated-safety-norms-says-fda yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/sanofi-s-dupixent-succeeds-in-copd-trial-india-cancels-licenses-of-18-drugmakers yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/incyte-s-skin-cancer-therapy-bags-fda-nod-biogen-s-als-drug-data-insufficient-says-panel yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pfizer-to-buy-seagen-for-us-43-bn-sanofi-to-acquire-provention-bio-for-type-1-diabetes-med yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/contaminated-syrups-caused-deaths-confirms-cdc-roche-exelixis-drug-combo-fails-kidney-cancer-trial yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pfizer-in-talks-to-buy-seagen-fda-panel-backs-pfizer-gsk-s-rsv-vaccines yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-okays-first-geographic-atrophy-med-pfizer-s-maternal-rsv-shot-bags-priority-review yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/gsk-kept-mum-about-zantac-cancer-risks-for-decades-sun-pharma-recalls-34-000-bottles-of-bp-med yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/drugmakers-to-face-covid-cliff-in-2023-gilead-s-trodelvy-approved-for-breast-cancer yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pfizer-crosses-us-100-billion-in-2022-sales-fda-okays-gsk-s-anemia-med-for-ckd-patients-on-dialysis yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-rejects-lilly-s-accelerated-nod-request-for-alzheimer-s-drug-who-expands-cough-syrup-deaths-probe yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/three-indian-drugmakers-receive-fda-s-form-483-merck-to-remove-cancer-causing-agent-from-diabetes-drugs yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-issues-form-483-to-intas-after-finding-docs-destroyed-by-staff-eisai-biogen-s-leqembi-bags-fast-track-nod yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/after-gambia-uzbekistan-links-child-deaths-to-indian-cough-syrup-us-congress-criticizes-fda-s-aduhelm-nod yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/india-s-api-prices-rise-due-to-china-s-covid-crisis-ferring-s-gene-therapy-becomes-first-bladder-cancer-med-in-us yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/amgen-buys-horizon-for-us-27-8-bn-takeda-snaps-up-nimbus-psoriasis-drug-for-up-to-us-6-bn yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pfizer-to-invest-over-us-3-billion-in-us-europe-sun-pharma-s-indian-facility-under-fda-s-import-alert yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fosun-mulls-stake-sale-in-gland-pharma-second-death-in-eisai-s-alzheimer-s-trial-raises-concerns yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-approves-first-gene-therapy-to-treat-hemophilia-b-teva-appoints-former-sandoz-chief-as-ceo yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fake-tweet-wipes-billions-off-lilly-s-market-cap-novartis-weighs-sale-of-two-units yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/sanofi-astra-s-rsv-med-bags-nod-in-europe-uk-gsk-s-blood-cancer-drug-flunks-late-stage-trial yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-steps-up-vigilance-on-indian-drugmakers-astra-s-imjudo-bags-first-nod-in-liver-cancer yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/after-pfizer-gsk-s-rsv-jab-shows-gains-in-late-stage-trial-alembic-s-india-site-gets-fda-s-form-483 yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-steps-up-user-fee-under-gdufa-iii-merck-s-heart-drug-succeeds-in-late-stage-study yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-approves-amylyx-s-als-drug-sk-capital-buys-canadian-generic-drugmaker-apotex yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/biogen-eisai-s-alzheimer-s-med-shows-benefit-in-late-stage-trial-lynparza-s-ovarian-cancer-nod-withdrawn yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/bluebird-ousts-its-own-gene-therapy-approved-last-month-as-world-s-costliest-catalent-hit-by-fda-s-form-483 yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/bms-sotyktu-wins-first-nod-in-plaque-psoriasis-revance-s-anti-wrinkle-drug-to-take-on-abbvie-s-botox yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novo-to-buy-forma-therapeutics-for-us-1-1-bn-boehringer-ingelheim-scores-its-first-dermatology-approval yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/moderna-sues-pfizer-biontech-over-mrna-technology-three-biocon-units-hit-by-fda-s-form-483s yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/gilead-s-hiv-drug-bags-its-first-nod-in-europe-pfizer-moderna-seek-fda-s-authorization-for-omicron-boosters yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/bluebird-bio-s-us-2-8-million-gene-therapy-bags-fda-nod-astra-s-enhertu-bags-second-approval-in-a-week yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pfizer-acquires-global-blood-therapeutics-for-us-5-4-billion-amgen-picks-up-chemocentryx-for-us-3-7-billion yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/us-court-rules-in-favor-of-abbvie-s-humira-patents-merck-s-keytruda-fails-in-two-late-stage-cancer-trials yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/teva-abbvie-announce-payouts-to-settle-opioid-lawsuits-roche-s-diagnostic-head-to-take-over-as-ceo-next-year yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/gsk-spins-off-haleon-pfizer-s-xalkori-bags-fda-nod-to-treat-rare-alk-positive-tumors yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/dr-reddy-s-india-facility-hit-by-fda-s-form-483-sanofi-s-hemophilia-drugs-show-promise-in-late-stage-trials yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/merck-likely-to-buy-seagen-for-us-40-billion-indian-facilities-of-glenmark-cipla-hit-by-fda-s-form-483 yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-to-lay-off-8-000-jobs-globally-jazz-pharma-s-cannabinoid-spray-fails-phase-3-trial yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/roche-s-alzheimer-s-drug-fails-clinical-trial-pfizer-to-buy-8-1-percent-stake-in-valneva-to-advance-lyme-disease-vaccine yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/gsk-unveils-new-logo-ahead-of-haleon-split-fda-panel-endorses-two-gene-therapies-from-bluebird-bio yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/bms-buys-turning-point-for-us-4-1-billion-roche-s-follicular-lymphoma-drug-bags-conditional-nod-in-eu yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/gsk-nabs-affinivax-for-up-to-us-3-3-billion-pfizer-to-exit-haleon-post-its-listing-next-month yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/ema-to-suspend-100-generics-tested-at-indian-cro-lilly-to-invest-us-2-1-billion-in-indiana-facility yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/glaxosmithkline-is-now-gsk-aurobindo-s-india-manufacturing-unit-hit-with-fda-s-form-483 yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pfizer-buys-biohaven-for-us-11-6-billion-fda-issues-form-483-to-sun-pharma-s-india-unit yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-clears-bms-heart-drug-camzyos-biogen-ceo-steps-down-after-struggling-with-alzheimer-s-drug yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-confirms-its-plans-of-thousands-of-layoffs-roche-s-breast-cancer-drug-fails-phase-2-trial yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/bms-nektar-end-us-3-6-billion-cancer-partnership-demand-for-pfizer-s-paxlovid-nosedives yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-plans-thousands-of-layoffs-as-part-of-global-rejig-pfizer-gets-new-cfo-signals-big-m-a-plans yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-merges-pharma-oncology-units-to-save-costs-senator-probes-merck-s-us-pre-tax-income yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/roche-s-breakthrough-immunotherapy-fails-phase-3-trial-fda-okays-second-booster-for-those-over-50 yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/sun-pharma-agrees-to-pay-us-485-mn-to-settle-ranbaxy-antitrust-cases-hdt-bio-accuses-emcure-of-rna-delivery-platform-theft yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/biogen-releases-longer-term-data-on-aduhelm-jhl-founders-to-face-prison-term-for-stealing-genentech-s-secrets yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/sacklers-strike-us-6-billion-deal-to-settle-opioid-lawsuits-teva-to-launch-first-generic-in-us-for-bms-revlimid yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/russia-ukraine-war-may-delay-over-200-clinical-trials-j-j-legend-s-car-t-therapy-bags-fda-nod yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/gsk-christens-consumer-health-unit-haleon-witnesses-file-complaint-against-bms-for-delaying-breyanzi-approval-process yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-issues-warning-letter-to-indiana-chem-port-s-india-facility-robert-califf-appointed-as-fda-chief yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pfizer-expects-to-cross-us-100-billion-in-2022-revenues-sanofi-unveils-new-corporate-identity yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/bill-tabled-for-unannounced-foreign-fda-inspections-novartis-ceo-dampens-prospects-of-sandoz-buyout yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-declines-approval-to-pfizer-s-pediatric-rare-disease-drug-j-j-on-lookout-for-m-as-in-biotech-medtech-space yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/gsk-rejects-unilever-s-us-68-4-billion-offer-for-consumer-healthcare-unit-fda-issues-warning-letter-to-aurobindo yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/court-tells-fda-to-hasten-release-of-approval-data-on-pfizer-s-jab-fda-rejects-biocon-viatris-application-for-insulin-aspart yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/teva-indicted-for-fueling-opioid-addiction-in-ny-theranos-founder-pronounced-guilty-for-duping-investors yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pfizer-s-oral-covid-drug-bags-authorization-in-us-biogen-slashes-price-of-its-alzheimer-s-drug-by-half yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pfizer-s-covid-19-pill-retains-89-percent-efficacy-works-on-omicron-csl-buys-vifor-for-us-11-7-billion yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/three-shot-course-of-pfizer-jab-neutralizes-omicron-abbvie-pfizer-lilly-drugs-hit-by-fda-s-strict-safety-warnings yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/drugmakers-test-vaccine-efficacy-against-omicron-fda-panel-recommends-merck-s-antiviral-despite-safety-concerns yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-may-have-a-buyer-for-sandoz-fda-suggests-alternative-approaches-to-assess-nitrosamine-risk yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/j-j-to-spin-off-consumer-biz-within-two-years-biden-nominates-califf-as-fda-chief yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-safety-review-to-hold-up-moderna-s-vaccine-for-teens-fda-raises-concerns-at-biocon-s-malaysia-site yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-may-divest-sandoz-unit-fda-advisors-back-pfizer-s-covid-jab-for-five-to-11-year-olds yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/white-house-unveils-plans-to-roll-out-jabs-for-5-to-11-year-olds-fda-authorizes-moderna-j-j-boosters yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/mi5-says-russian-spies-stole-design-of-astra-oxford-jab-sanofi-gsk-pfizer-bi-can-t-escape-zantac-lawsuits yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/merck-s-antiviral-covid-pill-halves-risk-of-hospitalization-who-recommends-malaria-vaccine-for-africa-s-children yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/cdc-finds-moderna-to-be-most-effective-covid-jab-two-indian-cros-under-fda-lens-over-data-integrity-issues yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pfizer-s-jab-bags-fda-authorization-as-booster-for-elderly-brazilian-police-raids-precisa-over-bharat-biotech-deal yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/japanese-sites-find-foreign-matter-in-pfizer-s-jab-fda-regulators-says-covid-shots-remain-effective-without-boosters yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/sanofi-roche-sobi-avantor-a-big-week-for-m-as-jak-inhibitors-to-carry-heart-safety-cancer-warnings yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-s-vaccine-leaders-step-down-stainless-steel-contaminant-found-in-moderna-lots-as-japan-suspends-more-batches yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pfizer-s-covid-jab-bags-fda-s-full-approval-fda-posts-inspection-observations-at-aurobindo-jubilant yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-authorizes-third-dose-of-mrna-vaccine-who-mission-on-origins-of-covid-19-had-faced-pressure-from-china yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/azido-impurity-in-sartan-drugs-triggers-recalls-softbank-becomes-one-of-roche-s-largest-investors yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-increases-user-fees-under-gdufa-ii-india-initiates-anti-dumping-probe-against-china-over-drug-intermediate yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/two-killed-in-blast-near-bayer-s-plant-in-germany-fda-rejects-industry-plea-to-extend-nitrosamine-deadline yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/india-reports-steep-rise-in-api-prices-us-26-billion-settlement-announced-to-resolve-opioid-lawsuits yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/phillip-morris-acquires-two-drug-firms-pfizer-who-remain-at-loggerheads-over-booster-shots yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/gsk-hits-back-at-elliot-supports-ceo-israel-says-pfizer-jab-only-64-effective-against-delta-variant yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pfizer-cdc-differ-on-need-for-vaccine-booster-shots-fda-warning-letter-to-lupin-reveals-repeat-violations yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/gsk-ceo-under-pressure-to-demerge-consumer-arm-by-mid-2022-biden-drops-plans-to-donate-astra-vaccine yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/lupin-receives-fda-warning-letter-for-somerset-plant-delta-variant-may-become-dominant-in-us yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/biden-announces-plan-to-make-crucial-drugs-in-us-fda-gives-controversial-nod-to-biogen-s-alzheimer-s-drug yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/who-announces-new-naming-system-for-covid-variants-fda-seeks-us-6-5-billion-from-biden-s-first-budget yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/europe-eases-travel-restrictions-pfizer-astra-s-vaccines-show-efficacy-against-b-1-617-2-indian-strain yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-to-invest-us-183-million-in-antibiotic-production-ema-fda-relax-storage-conditions-of-pfizer-s-vaccine yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/sanofi-allegedly-destroyed-emails-linked-to-zantac-recall-moderna-says-ip-waiver-won-t-increase-mrna-jabs-supply yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pfizer-expects-us-26-billion-in-2021-from-vaccine-sales-us-backs-vaccine-patent-waiver-plan-to-end-pandemic yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/russian-vaccine-rejected-over-concerns-that-adenovirus-can-reproduce-us-discusses-waiver-of-ip-rights-to-fight-pandemic yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-halts-production-at-j-j-s-vaccine-contractor-for-unsafe-practices-thermo-fisher-picks-up-ppd-for-us-17-4-billion yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/vaccine-cocktails-in-the-works-uk-china-france-consider-mixing-jabs-india-bans-exports-of-remdesivir yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/europe-confirms-link-between-astra-jab-and-clots-baltimore-plant-mixes-ingredients-of-j-j-astra-shots yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-shutters-plant-of-world-s-costliest-drug-bharat-biotech-s-vaccine-rejected-by-anvisa-due-to-gmp-concerns yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/chinese-prices-of-apis-increase-dramatically-former-operation-warp-speed-head-accused-of-sexual-harassment yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novavax-s-covid-vaccine-shows-96-percent-efficacy-gsk-merck-s-us-4-2-billion-cancer-drug-flops-again yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/teva-s-anti-competitive-practices-under-eu-scanner-fda-calls-out-khlo-kardashian-for-making-false-claims yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/us-eu-announce-plans-to-fortify-drug-supply-chains-fda-authorizes-j-j-s-single-shot-vaccine yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/indian-drugmakers-reducing-dependence-on-china-for-apis-pfizer-seeks-fda-ok-to-store-jab-in-standard-freezers yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/semaglutide-proves-effective-against-obesity-novartis-sandoz-buys-three-antibiotics-from-gsk yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/french-paracetamol-api-maker-s-majority-owner-looks-to-sell-out-mckinsey-pays-us-600-mn-to-settle-opioid-case yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/jazz-pharma-buys-cannabinoid-drug-maker-gw-pharma-for-us-7-2-billion-pfizer-s-covid-jab-to-bring-in-us-15-billion yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-starts-inspections-in-china-india-pfizer-moderna-work-on-booster-shots-against-covid-variants yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/former-merck-scientist-arrested-for-stealing-keytruda-s-trade-secrets-biden-appoints-new-interim-fda-chief yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pfizer-biontech-raises-2021-covid-19-vaccine-output-target-sanofi-s-api-business-to-be-called-euroapi yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pfizer-unveils-new-brand-identity-ema-fda-signal-delay-in-conditional-nod-to-astrazeneca-s-vaccine yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/nanoparticles-in-pfizer-s-vaccine-may-be-triggering-allergic-reactions-fda-declines-nod-to-novartis-blockbuster yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/mylan-pfizer-s-upjohn-combine-to-offload-15-plants-astra-buys-out-alexion-for-us-39-billion yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/ema-hit-by-cyberattack-that-accesses-vaccine-data-allergic-reaction-to-pfizer-vaccine-reported-in-uk yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/canada-stops-bulk-drug-exports-to-counter-america-s-new-rules-uk-grants-eua-to-pfizer-s-covid-vaccine yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/astrazeneca-s-vaccine-gilead-s-remdesivir-stumble-fda-finds-water-leakages-from-ceiling-at-aurobindo-s-us-facility yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/amazon-launches-online-pharmacy-fda-authorizes-first-self-test-home-kit-for-covid-19 yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pfizer-s-vaccine-more-than-90-percent-effective-biden-sets-up-coronavirus-task-force yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/us-approves-merger-of-pfizer-s-upjohn-with-mylan-biogen-may-deliver-first-alzheimer-s-drug yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/gilead-s-remdesivir-gets-fda-approval-to-treat-covid-19-bayer-buys-askbio-for-us-4-billion yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pfizer-shifts-timeline-of-covid-vaccine-to-november-remdesivir-slumps-in-who-s-solidarity-trial yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/european-study-highlights-reliance-on-asia-for-apis-mallinckrodt-files-for-bankruptcy-in-us yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/bms-buys-biopharma-firm-myokardia-for-us-13-1-billion-concerns-emerge-over-quality-of-acetazolamide yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/nature-releases-summary-of-all-vaccines-under-development-panacea-biotec-gets-fda-warning-letter yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/trump-says-pfizer-s-vaccine-likely-to-be-first-covid-vaccine-available-dr-reddy-s-settles-blockbuster-patent-suit-with-bms yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/gilead-acquires-immunomedics-for-us-21-billion-fda-issues-guidance-on-resuming-normal-manufacturing yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/ceos-pledge-to-prioritize-science-for-safe-covid-vaccine-astrazeneca-oxford-put-phase-3-trials-on-hold yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/another-mylan-unit-gets-fda-warning-letter-us-may-fast-track-covid-19-vaccine-says-fda-chief yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/teva-faces-drug-price-fixing-charges-to-cut-350-jobs-in-israel-wintac-gets-hit-by-fda-warning-letter yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/us-sues-teva-over-kickbacks-stock-drops-j-j-sanofi-announce-big-deals yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/kodak-s-us-765-million-loan-put-on-hold-digital-health-sees-its-biggest-deal-as-teladoc-buys-livongo yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-hikes-anda-dmf-application-fee-sanofi-faces-charges-of-manslaughter-in-france yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/kodak-fujifilm-get-millions-from-us-government-to-produce-drugs-trump-s-orders-to-check-drug-prices-upsets-industry yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/supply-chains-in-china-disrupted-by-severe-floods-us-accuses-two-chinese-nationals-of-stealing-covid-19-research yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pfizer-ceo-expects-covid-vaccine-approval-by-october-favipiravir-shows-inconclusive-results-against-covid-19 yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/china-approves-vaccine-candidate-for-military-use-big-pharma-joins-stop-hate-for-profit-discontinue-facebook-ads yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/us-buys-up-global-stocks-of-gilead-s-remdesivir-india-china-standoff-leads-to-supply-chain-woes yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-issues-covid-19-guidelines-for-drug-plants-mylan-scores-win-against-biogen-s-ms-drug-patent yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/dexamethasone-benefits-severely-ill-covid-patients-fda-warning-letter-to-takeda-s-sterile-operations-in-japan yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-defends-its-foreign-inspections-practices-who-resumes-hcq-solidarity-trials yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/sanofi-overhauls-executive-committee-fda-recalls-metformin-due-to-unacceptable-levels-of-ndma-impurity yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/who-halts-hcq-trials-for-covid-merck-vs-merck-mercky-saga-continues-akorn-files-for-bankruptcy yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/us-rolls-out-operation-warp-speed-announces-us-354-million-manufacturing-contract-for-essential-medicines yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/gilead-signs-deals-for-remdesivir-production-pfizer-outsources-drug-making-to-focus-on-covid-vaccine yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/trump-admin-wants-to-pull-global-supply-chains-out-of-china-fda-okays-remdesivir-for-emergency-use yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/covid-19-update-remdesivir-found-to-accelerate-recovery-in-key-trial-france-to-study-nicotine-patches-on-patients yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-compromised-standards-to-get-bayer-s-chloroquine-hcq-study-shows-no-benefits-higher-deaths-in-study yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/sanofi-gsk-join-hands-for-covid-19-vaccine-bms-awarded-us-1-2-billion-in-major-patent-case-win-over-gilead yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/india-partially-lifts-hydroxychloroquine-paracetamol-export-ban-delays-by-ftc-lead-to-nixing-of-us-1-billion-sandoz-deal yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-highlights-data-integrity-concerns-at-pfizer-s-india-unit-fda-requests-removal-of-all-ranitidine-products yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/covid-19-treatments-stumble-india-restricts-trump-backed-drug-hcq-exports-as-fda-lifts-ban-on-ipca-to-get-supplies yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/us-plans-to-reduce-drug-manufacturing-dependence-on-china-india-cross-contamination-problems-at-cipla yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/covid-19-update-indian-firms-airlift-apis-from-china-fda-suspends-foreign-inspections-pharma-events-get-cancelled yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/ema-raises-clinical-data-integrity-concerns-at-indian-cro-sandoz-to-pay-record-us-195-million-fine yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/world-takes-stock-of-covid-19-impact-on-drug-supply-chain-sanofi-to-create-major-european-api-firm yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/three-drugs-enter-human-trials-to-treat-covid-19-fda-anticipates-drug-supply-disruptions yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/us-indian-governments-reviewing-dependence-on-china-for-drugs-fda-finds-recurrent-failures-at-dr-reddy-s yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/merck-spins-off-slow-growing-drugs-into-us-6-5-billion-firm-aurobindo-s-facility-gets-classified-as-oai yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/insys-founder-sentenced-to-jail-in-opioid-case-ipsen-s-clementia-bet-misfires yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/cipla-in-fda-trouble-fda-backed-cannabis-drug-posts-strong-sales-in-launch-year yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/china-to-work-with-eu-on-aligning-api-standards-lupin-stumbles-with-fda-yet-again yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/2020-begins-with-drug-price-increases-in-us-and-mysterious-illness-in-china yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/test-fda-okays-gsk-s-exdensur-as-first-biologic-add-on-med-for-severe-asthma-issues-oai-status-to-sun-pharma-s-india-facility yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/data-integrity-concerns-at-sun-s-halol-plant-merck-s-ebola-vaccine-bags-fda-nod yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/gilead-loses-patent-case-to-bristol-myers-over-its-car-t-therapy-amneal-beats-dr-reddy-s-on-key-generic-approval yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/after-sartans-diabetes-drug-metformin-being-tested-for-cancer-causing-impurities-fda-s-overseas-inspections-drop yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/big-pharma-slash-prices-for-china-s-insurance-scheme-plan-major-investments-in-gene-therapy yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/teva-endo-may-go-bankrupt-in-a-year-says-study-novartis-buys-the-medicines-company-for-us-9-7-billion yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/chinese-plant-littered-with-rodent-feces-supplied-otc-products-to-us-recipharm-acquisition-spree-continues yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/mylan-s-valsartan-facility-gets-fda-warning-letter-us-sues-gilead-over-hiv-drug-patents yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/spanish-api-manufacturer-cited-for-data-integrity-violations-fda-recommends-new-system-to-rate-quality-of-drugmakers yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/sanofi-pulls-zantac-from-us-canada-fda-slams-chinese-api-manufacturer-dmf-guidance-update yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/former-ranbaxy-promoters-arrested-us-plans-tariffs-on-swiss-drug-exports yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/ema-pushes-for-review-of-all-chemically-synthesized-apis-for-nitrosamines-trump-s-order-decries-pelosi-s-drug-policy yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/lupin-s-fda-problems-continue-as-indian-site-receives-warning-letter-takeda-to-offload-otc-prescription-business yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/gsk-dr-reddy-s-halt-ranitidine-supplies-on-carcinogen-concerns-democrats-unveil-drug-pricing-plan yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/teva-subsidiary-inks-cannabis-deal-after-sartans-nitrosamine-impurities-scare-spreads-to-antacids yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-pledges-to-disclose-data-integrity-issues-faster-fda-uncovers-a-cascade-of-failure-at-ipca-labs-in-india yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/drug-mixup-in-spain-causes-werewolf-syndrome-in-children-explosion-at-plant-in-india-kills-12 yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/explosion-at-indian-api-manufacturer-new-drug-law-in-china-amgen-buys-celgene-s-blockbuster-for-us-13-4-billion yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-in-crisis-management-mode-elanco-buys-bayer-s-animal-health-business-for-us-7-6-billion yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/us-senator-seeks-unannounced-fda-inspections-nektar-reports-manufacturing-issues-with-lead-project yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/amneal-co-founders-return-to-run-company-drug-industry-urges-canada-to-act-on-us-drug-import-plan yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-releases-gdufa-ii-fee-for-fy20-teva-to-recover-settlement-charge-from-execs yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/apotex-blamed-for-fda-rejection-of-biohaven-s-new-drug-canada-opposes-trump-s-plan-to-import-drugs yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/biohaven-s-new-drug-fails-to-get-fda-nod-due-to-apotex-s-manufacturing-problems yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-sunny-forecast-for-sandoz-ceo-sets-aside-us-700-million-to-settle-bribery-lawsuit yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/canada-opposes-us-plans-to-import-drugs-phrma-steps-up-its-lobbying-spend yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pfizer-s-lyrica-goes-generic-with-10-copycats-price-down-nearly-98-percent yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/who-declares-ebola-emergency-congo-s-health-minister-resigns yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/appeals-court-upholds-criminal-conviction-of-shkreli-holmes-balwani-win-order yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/who-recommends-dolutegravir-as-preferred-hiv-treatment yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/sanofi-buys-otc-rights-in-us-for-roche-s-flu-treatment-tamiflu yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-uncovers-shredding-of-documents-at-strides-indoco-gets-another-warning-letter yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/indivior-loses-appeal-to-block-generic-suboxone-dr-reddy-s-allowed-to-market-drug yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/trump-administration-scraps-drug-rebate-proposal-may-target-drugmakers yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/seasoned-pharma-executive-jonathan-symonds-may-chair-gsk yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/astrazeneca-s-diabetes-treatment-fails-to-get-fda-nod-for-type-1-diabetes yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-uncovers-shredding-of-documents-at-strides-us-scraps-drug-rebate-proposal yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/manufacturing-concerns-at-apotex-lead-to-withdrawal-of-31-andas-us-working-on-executive-order-on-drug-prices yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-cites-manufacturing-concerns-at-apotex-s-india-facilities-withdraws-approval-of-31-andas yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/us-working-on-favored-nation-clause-to-source-drugs-judge-shoots-down-drug-price-in-ads-plan yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/teva-sells-its-us-store-brand-portfolio-to-pl-developments yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/cancer-deaths-cost-us-economy-us-94-billion-in-lost-earnings-says-study yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/janssen-walks-out-of-us-915-million-deal-with-korean-drugmaker-hanmi yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/roche-spark-s-us-4-3-billion-merger-deadline-now-pushed-to-april-2020 yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/former-inyx-chairman-convicted-for-fraud-that-led-to-collapse-of-puerto-rico-bank yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/gottlieb-joins-pfizer-s-board-faces-political-backlash yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/apple-launches-blood-glucose-monitor-sales-in-stores-integrated-with-iphone-and-watch yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-s-generic-approvals-slow-down-apple-launches-blood-glucose-monitor-sales-in-stores yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/us-lost-us-7-6-billion-since-2015-due-to-patent-walls-that-delayed-biosimilars yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-s-manufacturing-inspections-questioned-generic-approvals-slow-down yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/compliance-problems-at-strides-puducherry-unit-fda-posts-aurobindo-s-warning-letter yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/spc-waiver-to-remove-major-competitive-disadvantage-of-eu-drugmakers yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-german-chemical-distributor-named-in-controversial-supplies-to-syria yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/abbvie-buys-allergan-for-us-63-billion-fda-okays-controversial-women-s-libido-drug yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/abbvie-buys-botox-maker-allergan-for-us-63-billion yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-approves-controversial-women-s-libido-drug-vyleesi-rejects-daiichi-s-cancer-drug yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/akorn-aurobindo-get-warning-letters-sun-pharma-s-data-called-into-question yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/merck-starts-looking-for-a-new-ceo-shares-updates-on-activities-beyond-keytruda yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/bms-to-shed-celgene-s-psoriasis-drug-to-close-merger-gsk-split-activities-continue yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/debate-on-paclitaxel-coated-stents-continues-fda-releases-20-year-data-on-medical-devices yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/uk-launches-inquiry-after-news-of-unsafe-stolen-drugs-entering-nhs-supply-chain yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/teva-s-struggles-continue-fbi-probes-lead-to-purge-of-china-origin-scientists-from-us yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pfizer-beefs-up-its-oncology-portfolio-by-acquiring-array-for-us-10-64-billion yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/more-bad-news-from-teva-former-vp-conspired-to-raise-prices-of-107-generics-opioid-settlement-put-on-hold yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/data-theft-charges-fbi-probes-lead-to-purge-of-china-origin-scientists-from-us yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/bluebird-s-us-1-78-million-gene-therapy-to-rank-among-the-most-expensive-drugs yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/drug-firms-sue-us-government-over-tv-ads-ruling-catalyst-sues-fda-for-approving-rival-s-drug yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-usp-at-loggerheads-over-need-for-biologics-monographs yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/data-integrity-concerns-surface-at-aurobindo-pharma-s-india-unit yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/bankrupt-aceto-files-case-against-aurobindo-accusing-it-of-sabotage yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/insys-settles-opioid-case-files-for-bankruptcy-mallinckrodt-settles-drug-pricing-case yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fresenius-says-tighter-eu-rules-could-trigger-antibiotic-shortage yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-accepts-celgene-s-ozanimod-application-lilly-s-cluster-headache-drug-gets-nod yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/merck-buys-another-biotech-keytruda-wins-fda-nod-for-head-neck-cancer yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-paul-hudson-to-become-sanofi-s-new-ceo-data-integrity-concerns-surface-at-aurobindo-pharma yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/sanofi-finds-ceo-replacement-poaches-paul-hudson-from-novartis yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/us-china-trade-war-begins-to-impact-biotechs-heritage-pharma-settles-price-fixing-charges yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/heritage-pharma-settles-price-fixing-charges-dr-reddy-s-announces-china-plans yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/us-china-trade-war-begins-to-impact-biotechs-fosun-to-ease-up-on-us-investments yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pe-firms-gear-up-to-buy-bayer-s-animal-drugs-biz-bayer-ties-up-with-biotech-arvinas yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/breakthroughs-dominate-oncology-meet-in-chicago-fda-announces-project-facilitate yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/amgen-karyopharm-in-legal-war-over-exodus-of-sales-reps-novartis-gene-therapy-head-quits yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-wins-approval-of-world-s-most-expensive-drug-sun-pharma-looks-beyond-generics yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-has-25-potential-blockbusters-in-pipeline-takeover-targets-in-china-scarce-says-ceo yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/first-opioid-trial-begins-in-oklahoma-purdue-teva-reach-out-of-court-settlements yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/ftc-report-points-to-huge-drop-in-pay-for-delay-payments-to-generic-players yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/mit-researcher-accused-of-claiming-others-discoveries-as-his-own yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/uk-s-cma-alleges-price-gouging-by-four-firms-that-restricted-supply-of-nausea-drug yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/sun-pharma-plans-to-buy-innovative-firms-to-generate-revenue-from-patented-drugs yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/alkem-s-us-site-three-aurobindo-facilities-found-in-unacceptable-state-of-compliance yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/gilead-s-new-ceo-defends-hiv-prevention-drug-in-us-congress yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/sales-of-takeda-s-latam-biz-orchid-pharma-enter-final-stages-thermo-fisher-buys-gsk-site yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/monsanto-j-j-to-make-heavy-payouts-to-plaintiffs-in-roundup-vaginal-mesh-cases yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/ex-fda-chief-gottlieb-novartis-ceo-share-concerns-about-new-drug-cures yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/merck-to-acquire-peloton-for-us-1-05-billion yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-classifies-alkem-aurobindo-facilities-as-oai-new-ceo-defends-gilead-s-hiv-prevention-drug yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/new-book-on-quality-issues-in-generic-drugs-sends-fda-in-damage-control-mode yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/prescription-opioid-volume-in-us-dropped-43-percent-since-2011-peak-says-iqvia-report yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/abbvie-boehringer-resolve-us-patent-dispute-over-humira-biosimilar yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/takeda-sells-dry-eye-drug-to-novartis-in-us-5-3-billion-deal yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/drug-companies-in-us-mandated-to-put-list-price-in-tv-commercials yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/teva-20-other-generic-drugmakers-sued-by-44-state-coalition-in-us-over-price-fixing yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/new-book-on-quality-issues-in-generic-drugs-sends-fda-in-damage-control-mode-21-generic-firms-sued-over-price-fixing yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/insys-founder-kapoor-convicted-in-opioid-scandal-fda-rules-changing-due-to-new-technologies yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/billionaire-john-kapoor-found-guilty-in-bribery-scheme-to-drive-opioid-sales yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-s-inspection-at-torrent-raises-concerns-over-investigations-into-oos-results yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/sharpless-calls-for-nimble-fda-gottlieb-had-sought-changing-fda-rules-due-to-new-technologies yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/biosimilars-on-a-roll-biocon-s-potential-ipo-new-launches-by-fresenius-pfizer yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pfizer-s-rare-disease-drug-sanofi-s-dengue-vaccine-bag-fda-nod-lundbeck-buys-abide yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/ema-raises-ndma-impurity-concerns-in-diabetes-drug-made-by-hetero-shareholder-revolt-rocks-bayer yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/after-sartans-ema-raises-concerns-over-impurities-in-diabetes-drug-made-by-hetero yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/bayer-faces-shareholder-revolt-over-monsanto-buyout-and-weedkiller-lawsuits yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/french-regulator-warns-of-serious-complications-due-to-use-of-ibuprofen-ketoprofen yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/ema-tells-lilly-to-withdraw-cancer-drug-that-was-awarded-accelerated-approval yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/roche-announces-yet-another-extension-of-its-offer-to-buy-spark-for-us-4-3-billion yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/another-lupin-facility-gets-fda-s-oai-classification-layoffs-at-gsk-s-r-d-ops-sandoz-gets-new-ceo yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/after-gsk-lilly-and-genentech-md-anderson-ousts-scientists-over-data-theft yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/another-lupin-facility-gets-classified-as-an-oai-may-face-regulatory-action yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/emerging-biopharma-companies-account-for-72-percent-of-all-late-stage-pipeline-activity-says-iqvia-report yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/gsk-to-layoff-r-amp-d-staff-in-uk-us-due-to-rethink-on-its-drug-development-ops yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pharma-companies-spend-on-lobbying-nearly-touches-record-high-in-us yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/top-drugs-and-pharmaceutical-companies-of-2018-by-revenues yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/bms-celgene-mega-merger-gets-shareholder-nod-10-people-die-in-another-industrial-accident-in-china yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/the-big-five-by-sales-pfizer-novartis-roche-j-j-and-merck yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/humira-continues-to-be-top-seller-top-five-drugs-list-gets-a-rejig yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/top-15-drugs-by-sales yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/bms-celgene-mega-merger-gets-shareholder-approval-despite-investor-dissent yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/chinese-industry-to-see-tough-safety-norms-as-another-fire-takes-place-at-drug-firm yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/after-louisiana-s-netflix-model-sanofi-announces-us-99-plan-for-diabetics-in-us yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/catalent-makes-us-1-2-billion-bet-on-gene-therapy-manufacturer-paragon yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/dr-reddy-s-purchases-42-andas-in-us-to-augment-injectables-portfolio yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/takeda-puts-latam-business-on-the-block-cvc-partners-sells-doc-generici yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/apotex-explores-sale-perrigo-looks-at-selling-its-prescription-business-for-us-2-5-billion yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/apotex-explores-sale-perrigo-looks-at-selling-prescription-business-takeda-puts-latam-biz-on-the-block yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-declares-list-of-40-nitrosamine-free-valsartan-and-arb-class-drugs yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/eu-files-wto-case-against-turkey-over-unlawful-measures-on-pharmaceuticals yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-completes-alcon-spin-off-looking-for-more-acquisition-targets yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/astra-strikes-us-6-9-billion-oncology-deal-with-daiichi-cipla-jubilant-indoco-s-fda-inspection-updates yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/astrazeneca-bets-nearly-us-7-billion-in-cancer-drug-deal-with-daiichi-sankyo yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/https-www-pharmacompass-com-radio-compass-blog-astra-strikes-us-6-9-billion-oncology-deal-with-daiichi-cipla-jubilant-indoco-s-fda-inspection-updates yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/compliance-recap-fda-clears-indoco-s-india-facility-jubilant-s-valsartan-site-in-trouble yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/after-us-singapore-recalls-bp-drugs-made-with-hetero-s-nmba-tainted-losartan yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/outgoing-fda-chief-tells-companies-to-develop-pain-drugs-that-replace-opioids yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-pays-us-310-million-upfront-to-acquire-anti-inflammatory-drug-player-ifm-tre yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/another-massive-explosion-in-a-chemical-plant-rocks-china-lilly-discloses-drug-pricing-data-for-insulin yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/lilly-discloses-drug-pricing-data-for-insulin-amidst-mounting-federal-scrutiny yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-alcon-to-be-listed-on-six-swiss-exchange-and-nyse-on-april-9 yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/allergan-gives-in-to-appaloosa-s-demand-agrees-to-split-ceo-chairman-roles yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/span-style-font-size-18px-font-family-arial-span-style-font-size-18px-font-family-arial-p-span-style-font-size-18px-font-family-arial-so-far-men-have-had-little-birth-control-choices-other-than-using-condoms-or-going-in-for-a-vasectomy-researchers-have-be yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/j-j-and-bayer-settle-over-25-000-xarelto-lawsuits-in-us-for-us-775-million yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/purdue-pharma-oklahoma-crackdown-on-opioid-crisis-via-out-of-court-settlement yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-warns-of-death-risk-from-abbvie-s-venclexta-pfizer-merck-scrap-another-bavencio-trial yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/biogen-eisai-scrap-two-late-stage-trials-of-its-alzheimer-s-drug yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-raises-cgmp-concerns-at-lupins-us-india-units-sanofi-begins-hunt-for-new-ceo yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/sandoz-ceo-richard-francis-steps-down-reigniting-split-off-rumors yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-raises-cgmp-concerns-in-oai-letter-issued-to-lupin-s-sites-in-india-us yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/sanofi-begins-hunt-for-new-ceo-gilead-s-outgoing-ceo-bags-us-10-million-hike-in-compensation yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novo-gets-four-year-reprieve-in-us-from-teva-s-victoza-copycats yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fresh-data-from-reduce-it-study-shows-amarin-s-vascepa-cuts-heart-problems-by-30 yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/sanofi-and-abbvie-ceos-suffer-pay-cuts-fda-warning-letters-to-pfizer-jubilant-s-indian-operations yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/sanofi-and-abbvie-ceos-suffer-pay-cuts-post-row-over-mylan-ceo-s-salary-hike yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-issues-warning-letters-to-pfizer-s-site-in-south-india-and-jubilant-generics yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/tale-of-two-antidepressants-fda-approves-j-j-s-esketamine-rapastinel-s-failure-raises-pressure-on-allergan-ceo yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/celgene-files-ozanimod-in-europe-as-it-faces-pressure-on-mega-merger-with-bms yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pharma-bro-martin-shkreli-maybe-running-his-business-from-prison yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/nci-s-ned-sharpless-to-head-fda-in-wake-of-gottlieb-s-surprise-exit-last-week yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-approves-18th-biosimilar-fujifilm-grabs-biogen-s-biologics-plant-in-denmark yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/philippines-doj-prepares-charges-to-indict-sanofi-officials-over-dengue-vaccine-mess yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/third-cancer-causing-toxin-found-in-hetero-s-losartan-torrent-issues-fresh-recalls yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/biogen-to-acquire-nightstar-therapeutics-in-us-800-million-cash-deal yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-chief-gottlieb-resigns-bms-celgene-deal-may-get-derailed-due-to-shareholder-opposition yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-chief-resigns-a-day-after-taking-forceful-actions-against-tobacco-retailers yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/bms-celgene-s-us-74-billion-mega-merger-may-get-derailed-due-to-investor-opposition yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/amid-a-turbulent-year-and-falling-revenues-mylan-faces-more-flak-for-raising-ceo-s-salary yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/opioid-drugmaker-purdue-pharma-explores-bankruptcy-to-dodge-lawsuit-liabilities yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/data-integrity-concerns-at-dr-reddy-s-roche-ipsen-make-multi-billion-dollar-buys-aceto-files-for-bankruptcy yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/data-integrity-concerns-at-dr-reddy-s-problems-of-sterility-assurance-at-aurobindo yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/big-pharma-grilled-by-us-senators-on-drug-pricing-called-morally-repugnant yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/ge-sells-biopharma-business-to-danaher-corp-for-us-21-billion yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/roche-ipsen-make-multi-billion-dollar-buys-morningstar-speculates-on-future-m-as yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-issues-safety-risk-on-pfizer-s-xeljanz-the-most-advertised-product-on-tv yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/ftc-reaches-global-pay-for-delay-settlement-with-teva-aceto-files-for-bankruptcy yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fortis-seeks-arrest-of-malvinder-and-shivinder-singh-former-ranbaxy-promoters yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/teva-to-divest-11-sites-this-year-former-ranbaxy-promoter-files-criminal-compliant-against-brother yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/teva-to-shed-11-sites-in-2019-to-turn-to-the-high-priced-biotech-market-for-growth yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/embezzlement-by-ex-ranbaxy-promoters-pegged-at-us-282-million-malvinder-files-criminal-case yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/bayer-gains-licensing-rights-on-two-loxo-drugs-makes-headway-in-prostrate-cancer-drug yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/allergan-faces-flak-from-key-shareholder-post-appointment-of-ex-celgene-ceo-to-its-board yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/ich-seeks-to-standardize-generic-drugs-mit-research-team-develops-insulin-pill yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/leopard-tortoise-inspired-insulin-pill-may-help-replace-injections yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/ich-releases-reflection-paper-on-standardizing-generic-drugs yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/lupin-s-form-483-reveals-recurring-compliance-issues yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/takeda-to-pay-bayer-us-155-million-for-patent-infringement yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/j-j-to-become-first-company-in-the-us-to-put-list-prices-of-drugs-in-tv-commercials yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/sandoz-s-future-in-question-articles-on-risks-of-generic-drugs-has-fda-commissioner-justifying-inspection-focus yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-ceo-puts-sandoz-s-future-in-question-post-its-18-month-revamp-period yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/bloomberg-stories-on-risks-of-generic-drugs-has-gottlieb-justifying-inspection-focus-and-strategy yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/ema-asks-sartan-makers-to-review-manufacturing-process-alembic-accused-of-price-gouging yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/mylan-s-advair-generic-botox-rival-get-fda-nod-gsk-bets-big-on-oncology yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/to-accelerate-generic-competition-usp-unveils-generic-access-plan yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/as-more-sartan-recalls-are-announced-us-to-see-further-shortages-of-bp-medicines yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/j-j-s-imbruvica-bags-tenth-fda-nod-bms-withdraws-application-for-lung-cancer-drugs yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/big-pharma-prepares-for-no-deal-brexit-micro-labs-in-india-fails-edqm-inspection yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-opens-for-business-big-pharma-makes-plans-for-no-deal-brexit-novartis-sounds-alarm yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/micro-labs-fails-edqm-inspection-over-cross-contamination-fears yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/singapore-national-health-database-hacked-details-of-hiv-positive-patients-revealed yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/gsk-chairman-to-step-down-ahead-of-split-novartis-ceo-shares-updates-on-digital-healthcare yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-ties-up-with-oxford-s-big-data-institute-its-ceo-shares-updates-on-digital-healthcare yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/takeda-s-divestures-to-begin-soon-us-3-billion-of-emerging-market-assets-to-be-sold yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/j-j-abbvie-s-star-product-suffers-setback-lilly-suspends-latruvo-promotion yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/gsk-chairman-philip-hampton-to-step-down-ahead-of-split yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/india-s-aurobindo-acquires-cancer-specialist-spectrum-s-marketed-portfolio-for-us yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/governance-concerns-continue-to-loom-over-sun-pharma-with-second-whistleblower-complaint yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-running-out-of-funds-amid-shutdown-pfizer-lilly-astrazeneca-cut-jobs yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-says-it-s-running-out-of-funds-to-restart-food-inspections-despite-shutdown yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/efpia-prepares-list-of-actions-that-need-to-be-taken-in-event-of-no-deal-brexit yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/ema-shifts-to-amsterdam-may-lose-quarter-staff-post-relocation yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pfizer-lets-go-of-researchers-astra-lays-off-workers-in-us-lilly-cuts-jobs-in-france yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/gmp-violations-at-major-chinese-drugmaker-lupin-sun-recall-products-from-us yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/us-lawmaker-launches-probe-into-drug-pricing-teva-reaches-drug-pricing-settlement yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/jp-morgan-healthcare-meet-ends-with-discussion-on-relocating-out-of-san-francisco yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pfizer-announces-shutdown-of-two-manufacturing-sites-in-india-that-employ-1-700-people yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/eli-lilly-to-buy-loxo-oncology-for-about-us-8-billion-in-cancer-drug-bet yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/gottlieb-tweets-on-how-the-us-government-shutdown-will-impact-fda-generic-drug-firms yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/sartan-recall-affects-taiwanese-firm-torrent-aurobindo-recall-drugs-in-us yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/china-s-bulk-buy-policy-hits-gross-margins-of-domestic-drug-companies yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/in-the-us-drug-companies-kick-off-2019-with-price-hikes-albeit-at-a-slower-rate yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/india-mandates-75-percent-local-content-in-pharma-products-via-make-in-india-plan yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/2019-opens-to-biggest-pharma-deal-ever-pfizer-announces-shutdown-of-two-plants-in-india yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/bristol-myers-squibb-celgene-ring-in-the-new-year-with-us-74-billion-deal yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-proposes-limits-on-sartan-nitrosamine-impurities-text-messages-add-new-twist-to-us-generic-price-fixing-litigation yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/a-smiley-faced-text-message-is-at-the-center-of-generic-price-fixing-lawsuit yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-proposes-limits-on-nitrosamine-impurities-torrent-recalls-losartan-made-with-hetero-s-api yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-s-interim-limits-for-ndma-and-ndea-in-angiotensin-ii-receptor-blockers-arbs yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/in-the-us-big-pharma-to-ring-in-the-new-year-with-price-hikes yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/ftc-opens-teva-s-plea-to-modify-decision-regarding-watson-s-acquisition-of-actavis yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/this-year-too-eu-inspectors-uncover-data-integrity-violations-at-kores-india yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pfizer-gsk-to-merge-consumer-health-units-j-j-stock-plummets-after-talc-expos yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pfizer-gsk-to-merge-their-consumer-health-units-spin-off-jv-in-three-years yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/j-j-announces-us-5-billion-share-buyback-post-expos-on-its-talc yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/takeda-s-credit-rating-cut-by-three-notches-on-elevated-debt-concerns-after-shire-deal yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/gilead-gets-new-ceo-fda-poaches-number-two-from-flatiron-health yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-s-push-for-kasa-platform-over-ectd-tops-raps-list-of-most-read-articles-of-2018 yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/bms-sells-otc-unit-to-taisho-lilly-in-dealmaking-mode-merck-buys-animal-health-firm yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/america-s-generic-price-fixing-probe-widens-to-300-drugs-rift-between-ranbaxy-s-singh-brothers-gets-physical yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/america-s-generic-price-fixing-probe-expands-to-include-300-drugs-and-16-firms yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/rift-between-ranbaxy-s-singh-brothers-gets-physical-daiichi-moves-contempt-plea yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/drug-pricing-concerns-due-to-new-govt-program-drive-down-pharma-stocks-in-china yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/akorn-reconciles-to-court-verdict-ceo-steps-down-over-failed-fresenius-buyout yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/chinese-companies-announce-major-investments-to-combat-mnc-players yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/after-bayer-announced-job-cuts-its-top-drug-fails-and-investor-pushes-for-split yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/sanofi-and-boehringer-announce-job-cuts-in-france yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/bayer-to-cut-12-000-jobs-gsk-buys-cancer-drugmaker-tesaro-for-us-5-billion yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/bayer-reveals-plans-to-slash-12-000-jobs-over-1-000-employees-protest yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/gsk-makes-big-oncology-play-buys-tesaro-for-us-5-billion yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/sun-s-corporate-governance-in-question-stock-in-free-fall yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/sartan-case-aurobindo-walmart-sued-teva-recalls-drugs-made-with-mylan-s-api yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/study-finds-generic-drug-prices-were-strongly-predictive-of-drug-shortages yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/basf-unveils-company-wide-restructuring-to-expand-china-operations yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/heparin-concerns-emerge-once-again-as-chinese-firm-fails-edqm-inspection yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/expose-on-medical-device-failures-and-outrage-over-birth-of-genetically-edited-babies-in-china-grips-pharma-world yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/investigative-reports-on-medical-devices-prods-fda-to-overhaul-approval-process yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/birth-of-first-genetically-edited-babies-using-crispr-tools-stirs-global-outrage yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-approves-second-tissue-agnostic-cancer-drug-vitrakvi yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/teva-s-epipen-isn-t-cheaper-launched-at-same-price-as-mylan-s-generic-version yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/sun-pharma-to-consolidate-us-operations-invests-in-japanese-dermatology-business yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/astrazeneca-fails-big-trial-begins-search-for-ceo-sandoz-recalls-losartan-in-the-us yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/korean-regulator-says-samsung-biologics-intentionally-breached-accounting-rules yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/sandoz-recalls-losartan-with-ndea-impurity-fda-publishes-q-as-on-sartan-saga yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/astrazeneca-fails-big-trial-for-imfinzi-signs-deal-with-sobi-and-begins-search-for-ceo yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/arena-signs-deal-with-united-therapeutics-sanofi-gets-positive-ema-opinion-on-rare-disease-drug yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/google-novartis-halt-work-on-glucose-monitoring-smart-lens yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-explores-ways-to-reduce-animal-studies-for-developing-veterinary-drugs yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-announces-new-initiatives-for-inspections-and-clinical-trials-moderna-files-for-biotech-s-biggest-ipo yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-announces-new-initiatives-for-inspections-and-clinical-trials yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/takeda-on-track-to-close-us-62-billion-shire-deal-says-ceo yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/after-allergan-pfizer-plans-to-sell-its-women-s-health-unit-will-it-succeed yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/amarin-s-breakthrough-fish-oil-drug-for-heart-patients-comes-with-big-caveats yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/moderna-to-list-on-wall-street-with-us-500-million-ipo-biotech-s-biggest-yet yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-approves-first-flu-drug-in-20-years-trump-proposes-global-index-to-check-drug-price-rise yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/trump-proposes-global-pricing-index-model-for-medicare-part-b-program yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-approves-first-flu-drug-in-20-years-shionogi-expects-us-3-billion-in-sales yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/lundbeck-s-new-schizophrenia-treatment-fails-phase-iii-trial yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/j-j-s-blockbuster-prostate-cancer-drug-loses-patent-battle yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/after-eli-lilly-and-gsk-former-genentech-employees-caught-stealing-trade-secrets yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/after-europe-bans-irbesartan-made-by-aurobindo-fda-announces-its-recall-in-us yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/recipharm-s-uk-facility-fails-gmp-inspection-fda-proposes-harmonization-of-standards-for-generic-drugs yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/leading-cdmo-recipharm-s-uk-facility-fails-gmp-inspection yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-proposes-harmonization-of-global-standards-for-generic-drugs yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-makes-a-second-bet-on-radiology-buys-endocyte-for-us-2-1-billion yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/china-slaps-us-1-3-billion-fine-on-firm-caught-in-vaccine-scandal yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/astrazeneca-s-lynparza-can-put-brakes-on-ovarian-cancer yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/aurobindo-s-sartan-banned-in-europe-dr-reddy-s-cost-optimization-drive-continues-sells-off-another-site yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/dr-reddy-s-cost-cutting-measures-gain-momentum-divests-api-manufacturing-site yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/after-huahai-s-valsartan-aurobindo-stopped-from-supplying-irbesartan-into-europe yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-releases-method-to-detect-ndma-and-ndea-issues-clarification-on-import-alert yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/j-j-gets-key-label-expansion-for-its-blood-thinner-xarelto yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pfizer-rejigs-top-brass-gets-chief-digital-officer-on-board yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/biosimilars-of-world-s-best-selling-drug-humira-go-on-sale-this-week-in-europe yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/cancer-researchers-bag-nobel-prize-fresenius-wins-case-over-terminating-merger-with-akorn-due-to-data-integrity-issues yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/cancer-researchers-awarded-nobel-prize-for-medicine yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pfizer-gets-new-ceo-merck-extends-retirement-of-existing-one yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/lilly-bags-fda-approval-for-migraine-drug-may-give-it-for-free-to-insured-patients yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fresenius-wins-case-over-terminating-merger-with-akorn-due-to-data-integrity-issues yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/dr-reddy-s-sells-its-antibiotics-plant-in-us-to-uae-s-neopharma yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/new-twists-to-sartan-impurities-saga-fish-oil-drug-makes-heart-medicine-history yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/valsartan-saga-fda-posts-observations-at-huahai-ema-expands-review-class-action-suit-filed-in-ny yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/amarin-s-fish-oil-drug-shows-25-percent-drop-in-serious-cardiovascular-outcomes yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-to-cut-2-150-jobs-in-switzerland-novo-to-slash-400-in-denmark-china yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-continues-its-tech-investments-signs-deal-with-china-s-tencent yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/gilead-to-launch-generics-of-its-hepatitis-c-virus-treatments-via-new-subsidiary yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-seeks-to-clean-image-links-employee-bonuses-to-ethics-ema-fda-probe-new-impurity-in-valsartan yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-ema-report-presence-of-new-impurity-in-valsartan-produced-at-huahai yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-seeks-to-clean-image-by-linking-employee-bonuses-to-their-ethics-scorecard yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/teva-finally-wins-approval-for-migraine-drug-gets-embroiled-in-employee-suit yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-announces-a-string-of-measures-to-fight-the-menace-of-antibiotic-resistance yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/allergan-defuses-botox-threat-through-buyout-sun-wins-approval-for-novel-drug yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/under-new-listing-rules-hong-kong-stages-second-biotech-ipo yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/our-view yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-unloads-troubled-us-generics-to-aurobindo-investors-in-mylan-teva-unhappy yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/sun-pharma-and-dr-reddy-s-rework-strategy-to-deal-with-us-market-pressures yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/us-launches-civica-rx-to-tackle-high-prices-as-fda-gets-set-to-approve-record-andas yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/ex-teva-chairman-charged-in-pump-and-dump-stock-fraud yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/span-style-font-family-arial-font-size-18px-color-fc0d1b-gsk-suffers-setback-as-its-asthma-drug-fails-to-win-expanded-fda-approval-for-copd yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/sun-dr-reddy-s-rework-strategies-to-deal-with-us-market-novartis-sells-troubled-us-biz-to-aurobindo yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/emergent-biosolutions-billion-dollar-shopping-spree yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novo-bags-new-diabetes-technology-by-acquiring-bristol-univ-spinout-ziylo yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/german-cancer-startups-announce-big-ticket-deals yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-plans-job-cuts-in-switzerland-researcher-pleads-guilty-of-stealing-gsk-s-trade-secrets yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/former-gsk-researcher-admits-conspiring-to-steal-trade-secrets yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-to-cut-jobs-in-switzerland-teva-outsources-manufacturing-to-israel-s-rekah yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/brexit-fallout-begins-mhra-loses-ema-contracts-britain-s-gdp-down-2-percent yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/new-age-sglt2-diabetes-drugs-may-cause-flesh-eating-genital-infection yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/data-integrity-concerns-in-japan-at-kyowa-hakko-china-biotech-plant-explosion-probe yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-uncovers-data-integrity-concerns-at-kyowa-hakko-in-japan yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/after-vaccine-scandal-china-acts-on-those-responsible-for-juxin-explosion yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/tech-billionaires-move-innovative-new-drug-developments-forward yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/takeda-s-bet-on-shire-begins-to-pay-off-key-drug-bags-fda-approval yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/astrazeneca-s-new-inhaler-fails-to-match-gsk-s-drug-in-a-clinical-trial yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-ema-highlight-more-concerns-over-apis-being-sourced-from-china yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-ema-highlight-more-concerns-over-apis-from-china-fda-slams-apotex-s-india-operations yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/headwinds-at-mylan-chinese-api-adulteration-concerns-trigger-another-us-drug-recall yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/high-level-exit-at-dr-reddy-s-drug-stockpiling-starts-as-firms-face-no-deal-brexit-blues yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-releases-gdufa-ii-fee-for-fy19-astrazeneca-probed-on-bribes-to-iraqi-terrorists yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/aceto-wins-case-for-use-of-foreign-api-in-us-government-contracts-gsk-may-split yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pfizer-s-halts-manufacturing-post-fda-inspection-in-india-aurobindo-buys-apotex-s-european-operations-in-5-countries yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pfizer-rejigs-into-three-businesses-cancer-causing-impurity-in-china-made-api-leads-to-major-eu-drug-recall yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/amazon-buys-online-pharmacy-pillpack-novartis-spins-off-alcon-to-its-shareholders yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-updates-list-of-drugs-with-no-patents-no-competition-approves-first-marijuana-based-drug yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/dr-reddy-s-restrained-from-rolling-out-generic-opioid-addiction-drug-fda-rejects-mylan-s-advair-generic yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/global-drug-sales-to-hit-us-1-2-trillion-by-2024-gates-launches-biotech-startup yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/phrma-publishes-list-of-us-cancer-drug-pipeline-biocon-mylan-s-neulasta-biosim-bags-fda-nod yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/pfizer-s-manufacturing-woes-continue-iqvia-s-global-oncology-trends-fda-quality-alerts yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/astrazeneca-s-shareholders-rebel-over-ceo-pay-fda-lashes-out-at-iqvia-over-erroneous-data yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/as-novartis-gets-embroiled-in-payments-scandal-trump-unveils-drug-pricing-plan yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/teva-to-exit-80-percent-generics-portfolio-in-us-takeda-clinches-shire-for-us-62-billio yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fresenius-claims-blatant-fraud-at-akorn-court-delays-teva-s-layoff-schedule yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/takeda-to-buy-shire-for-us-65-billion-fresenius-dumps-akorn-over-data-integrity-concerns yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/advent-may-acquire-sanofi-s-european-generic-unit-shire-sells-cancer-unit-to-servier yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-buys-gene-therapy-for-us-8-7-billion-france-to-target-healthcare-for-its-ai-strategy yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/takeda-eyes-shire-may-pay-over-us-50-billion-fda-to-speed-up-approval-of-biosimilars yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/china-sees-sharp-rise-in-u-s-generic-approvals-gsk-opts-out-of-pfizer-s-otc-business-race yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-maintains-silence-on-quality-metrics-program-pharma-ceo-salaries yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/china-to-revamp-cfda-structure-fda-chief-highlights-problems-with-us-drug-pricing yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/uber-launches-uber-health-more-countries-join-fda-eu-mutual-recognition-program yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/japan-approves-drug-that-cures-flu-in-as-soon-as-24-hours-teva-repositions-brand-shuts-offices-in-us yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/serious-fraud-probe-against-former-ranbaxy-owners-gilead-wins-reversal-of-us-2-54-billion-hepatitis-c-patent-verdict yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/fda-seeks-changes-in-180-day-exclusivity-for-generics-data-integrity-concerns-at-bayer-s-german-facility yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/data-integrity-concerns-in-japan-fire-at-sun-pharma-s-api-facility-teva-raises-cash yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/apotex-s-founder-was-murdered-its-president-resigns-daiichi-to-recover-551-million-from-ranbaxy-promoters-semler-sues-usfda yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/a-week-of-us-20-billion-deals-teva-s-asthma-drug-fails-to-deliver-to-layoff-200-in-us yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/china-s-pollution-tax-to-roll-out-from-april-teva-directors-undergo-pay-cut yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/india-bans-drugs-from-six-chinese-api-firms-fda-takes-steps-to-speed-up-generic-approvals yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/2017-closes-with-record-approvals-of-generics-novel-drugs-2018-begins-with-reprieves-for-teva yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/teva-s-restructuring-plan-causes-furore-in-israel-apotex-founder-wife-found-dead yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-considering-a-sale-of-sandoz-s-oral-solids-business-sanofi-s-dengue-vaccine-found-to-make-disease-worse yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-considering-a-sale-of-sandoz-s-oral-solids-business-sanofi-s-dengue-vaccine yearly 0.7 https://www.pharmacompass.com/radio-compass-phisper/novartis-sues-us-govt-over-medicare-drug-price-regulation-ftc-okays-amgen-horizon yearly 0.7